8-K: Vivos Therapeutics Completes Strategic Acquisition of Nevada's Largest Sleep Center, Secures Over $11 Million in New Financing

Vivos Therapeutics, Inc. has successfully acquired the operating assets of The Sleep Center of Nevada, marking a significant pivot in its business model and securing over $11 million in new debt and equity financing to fund the acquisition and support future growth.

Summary

• Vivos Therapeutics, Inc. (NASDAQ: VVOS) has completed the acquisition of the operating assets of The Sleep Center of Nevada (SCN), the largest operator of medical sleep centers in Nevada.
• The acquisition involved a cash payment of $6.0 million and 607,287 shares of restricted common stock valued at $1.5 million, with a potential contingent earn-out of an additional $1.5 million in restricted common stock based on financial milestones.
• This transaction signifies a strategic pivot for Vivos, shifting its focus from a dental provider network to collaborating with and acquiring medical sleep practices to capture diagnostic and consultation revenue, and directly provide Vivos's FDA-cleared OSA treatments.
• SCN sees approximately 3,000 new patients per month for sleep disorder testing and consultation, with about 90% testing positive for OSA or other sleep disorders.
• Vivos secured a senior, non-convertible, secured term loan of $8,250,000 from Streeterville Capital, LLC, which included a $675,000 original issue discount and $50,000 for transaction costs, resulting in gross proceeds of $7,500,000.
• The loan bears an interest rate of 9% per annum, matures in 18 months, and is secured by all tangible and intangible assets of Vivos's wholly-owned subsidiary, Airway Integrated Management Company, LLC (AIM).
• An affiliate of existing investor New Seneca Partners, V-Co Investors 2 LLC, made a $3,755,000 private placement investment, consisting of 828,000 common shares, a pre-funded warrant for 725,258 shares (exercise price $0.0001), and a common stock purchase warrant for 2,329,886 shares (exercise price $2.23).
• The total gross proceeds from the loan and equity investments exceed $11 million, intended to fund the SCN acquisition and provide general working capital.
• Dr. Prabhu Rachakonda and Dr. Tara Rachakonda, board-certified sleep specialists and SCN's leaders, have joined Vivos and will continue managing the practice, with Dr. Prabhu Rachakonda receiving an annual compensation of $400,000 plus bonus incentives and a board observation right.
• Vivos will manage SCN through Practice Administration Agreements (PAAs) with monthly administration fees totaling $300,000 ($200,000 from SCN and $100,000 from SCN PLLC), adjustable quarterly, with a 15-year term.

Sentiment

Score: 7

Explanation: The document reflects a strong positive strategic move with the acquisition and a significant capital raise to support it. Management comments are highly optimistic about the business model pivot and its revenue potential. However, the financial terms of the debt, including a high OID, interest rate, and potential monitoring fee, introduce some financial burden and risk, tempering the overall positive sentiment.

Positives

• The acquisition of The Sleep Center of Nevada (SCN) provides Vivos with direct access to a high volume of patients (approximately 3,000 new patients per month) for OSA diagnosis and treatment.
• The strategic business model pivot is expected to generate new, higher-margin revenue streams from diagnostic and consulting services, in addition to Vivos appliance sales.
• The integration plan includes equipping and staffing SCN locations to offer Vivos treatment, with an anticipated ramp-up in diagnostic and appliance treatment revenues over 12-18 months.
• The continued involvement of SCN's founders, Dr. Prabhu Rachakonda and Dr. Tara Rachakonda, who are board-certified sleep specialists and are undergoing Vivos treatment themselves, provides strong leadership and endorsement.
• The total gross proceeds of over $11 million from the senior secured loan and private placement provide significant cash resources for the acquisition and general working capital, aiming to reduce cash burn and move towards cash flow positivity.

Negatives

• The senior secured loan includes a substantial original issue discount of $675,000 and an additional $50,000 for transaction costs, reducing the net proceeds received by the company.
• The loan carries a 9% annual interest rate, which is relatively high, and a potential monitoring fee if the note remains outstanding on its 120-day anniversary, further increasing the cost of debt.
• A prepayment premium of 107% applies if the company prepays the loan within 120 days, limiting early repayment flexibility without incurring additional cost.
• The private placement involved the issuance of common stock and warrants, which will result in dilution for existing shareholders.
• The company is obligated to file a registration statement for the resale of the newly issued securities, incurring additional legal and administrative costs.

Risks

• The risk that Vivos may be unable to service and ultimately repay its new senior debt facility.
• The risk that Vivos may be unable to successfully integrate SCN's business into its own operations or effectively implement new sales, marketing, and other strategies to increase revenues and cash flows.
• The risk that some patients may not achieve the desired results from using Vivos products, impacting patient satisfaction and treatment efficacy.
• Risks associated with regulatory scrutiny and adverse publicity within the sleep apnea diagnosis and treatment sector.
• The risk that Vivos may be unable to secure additional financing on reasonable terms when needed, if at all, or maintain its Nasdaq listing.
• The potential for the Administration Fee structure in the Practice Administration Agreements to be challenged by regulatory bodies, requiring revisions or even termination of the agreements.
• The exclusivity provisions in the Practice Administration Agreements and Physician Employment Agreement could face legal challenges related to corporate practice of medicine laws in Nevada.

Future Outlook

Vivos Therapeutics anticipates that the acquisition of The Sleep Center of Nevada will significantly ramp up its diagnostic and appliance treatment revenues over the next 12 to 18 months as additional SCN locations are fully integrated. The company expects this strategic pivot to meaningfully augment SCN's existing revenues, significantly reduce Vivos's cash burn, and move the company towards cash flow positivity. Vivos is actively pursuing additional collaborations or acquisitions to further expand its business during 2025 and beyond.

Management Comments

• R. Kirk Huntsman, CEO: "We are extremely pleased to get this first acquisition under our belt and are excited to reap the benefits of our business model pivot."
• R. Kirk Huntsman, CEO: "We started booking SCN patients over the past few weeks in anticipation of closing, and we are already fully booked out for the entire month of June and into late July with OSA patients seeking alternatives to CPAP and other less effective legacy OSA treatments."
• R. Kirk Huntsman, CEO: "The high level of enthusiasm for Vivos began with our new team members, Dr. Prabhu Rachakonda and Dr. Tara Rachakonda, both accomplished board-certified sleep specialists, who were themselves among the first patients to be treated."
• R. Kirk Huntsman, CEO: "With that kind of leadership, it’s easy to understand our enthusiasm for this acquisition and the prospects for similar transactions in the future as we seek to ramp our revenue significantly."
• Dr. Prabhu Rachakonda, SCN Founder: "We are truly excited to be a part of the Vivos team and bring this revolutionary, patented and FDA cleared treatment to our practice."
• Dr. Prabhu Rachakonda, SCN Founder: "Because of Vivos, we finally have what we believe is a real solution for OSA, a worldwide debilitating medical condition."
• Dr. Prabhu Rachakonda, SCN Founder: "My daughter and I believe in this so strongly that we are undergoing Vivos treatment ourselves."
• Dr. Prabhu Rachakonda, SCN Founder: "No one should have to endure a lifetime of nightly CPAP when there is a highly effective, patient friendly treatment available that offers the prospect of complete resolution of symptoms."
• Dr. Prabhu Rachakonda, SCN Founder: "We look forward to working with Vivos on scaling our business and offering the exciting portfolio of Vivos treatments to our patients."
• Michael Skaff, Managing Director of New Seneca Partners: "We have been in lockstep with Vivos management as they’ve executed on this strategic pivot toward affiliations with and acquisitions of sleep medicine and sleep testing centers."
• Michael Skaff, Managing Director of New Seneca Partners: "Our follow-on equity investment alongside the new senior debt lender reflects our significant enthusiasm and commitment to what Vivos is doing and the potential within their new model."
• Michael Skaff, Managing Director of New Seneca Partners: "We fully expect the benefits to Vivos will be significant and will scale as this transaction matures and higher volumes of patients get treated."
• Michael Skaff, Managing Director of New Seneca Partners: "With the SCN acquisition, Vivos now has direct access to patients, which sleep testing centers such as SCN have in abundance."
• Michael Skaff, Managing Director of New Seneca Partners: "SCN’s existing revenues will be meaningfully augmented in several important ways, all of which we expect to significantly reduce Vivos cash burn and move Vivos towards cash flow positivity."

Industry Context

This acquisition and strategic pivot by Vivos Therapeutics align with a broader trend in the healthcare industry towards integrated care models, particularly in specialized fields like sleep medicine. By acquiring a large sleep testing center like SCN, Vivos is moving beyond being solely a device manufacturer and network provider to directly control patient diagnosis and treatment pathways. This allows for greater capture of the patient value chain, from initial diagnosis to long-term treatment, and positions Vivos to compete more directly with traditional OSA treatments like CPAP by offering its FDA-cleared oral appliances as a primary solution. The focus on high-volume centers and higher-margin revenues reflects a common strategy for scaling specialized healthcare services and improving financial performance.

Comparison to Industry Standards

• NA The document does not provide specific comparable companies, projects, or results to assess against global benchmarks. The focus is on the company's internal strategic shift and its anticipated benefits.

Management Changes

Corporate Governance

Legal Proceedings

• The Company represents that there are no pending or threatened actions, suits, inquiries, or investigations against it or its subsidiaries that could reasonably be expected to result in a Material Adverse Effect, except as disclosed in SEC Reports.

Related Party Transactions

• The assigned lease agreements for SCN's operating premises (Red Rock Medical Center, Eldorado Medical Center, and 5751 South Fort Apache Road) are with entities managed by the Seller Principal (Dr. Prabhu Rachakonda). These leases are stated to be on fair market terms.
• V-Co Investors 2 LLC, a key investor in the PIPE Offering, is an affiliate of New Seneca Partners Inc., an existing significant private equity investor in Vivos.

Stakeholder Impact

• Shareholders: Experience dilution from the issuance of new common stock and warrants, but potentially benefit from the strategic pivot aimed at increasing revenue and moving towards cash flow positivity. Increased debt levels introduce higher financial risk.
• Employees: SCN's existing physicians and staff, including Drs. Prabhu and Tara Rachakonda, are integrated into Vivos's operations, ensuring continuity and leveraging their expertise.
• Customers (Patients): Gain access to Vivos's FDA-cleared, non-invasive OSA treatment options, potentially offering a more effective alternative to traditional therapies like CPAP.
• Creditors: Streeterville Capital, LLC becomes a senior secured creditor with a security interest in AIM's assets and a pledge of AIM's membership interests, providing collateral for their loan.
• Suppliers: Potential for increased demand for Vivos's oral appliances and related services as the SCN locations are integrated and patient volume for Vivos treatments grows.

Next Steps

• Vivos will manage and capture diagnostic and consulting revenues, as well as potential Vivos appliance sales revenue from SCN, effective immediately.
• Vivos plans to build out additional SCN locations over the next 12 to 18 months to offer Vivos treatment, expecting a ramp-up in diagnostic and appliance treatment revenues during this period.
• The company intends to use the net proceeds from the financings for general working capital purposes.
• The company is required to file a registration statement on Form S-3 (or S-1) for the resale of the PIPE Shares, PFW Shares, and Warrant Shares no later than 45 days from the closing of the PIPE Offering.
• Vivos must use commercially reasonable best efforts to cause the resale registration statement to be effective within 90 days of the PIPE Offering closing and keep it continuously effective for three years.
• Vivos is currently pursuing additional collaborations or acquisitions to expand its business further during 2025 and beyond.

Key Dates

Recommendation

Keywords

Vivos Therapeutics, The Sleep Center of Nevada, Obstructive Sleep Apnea, OSA treatment, Medical sleep centers, Acquisition, SEC filing, Form 8-K, Senior secured loan, Private placement, Equity financing, Warrants, Corporate practice of medicine, Healthcare acquisition, Sleep disorder diagnosis, Oral appliance therapy, Strategic pivot, NASDAQ, VVOS